Key facts
- Mendel’s last known valuation is $118.0M (Mar 2022).
- It has raised $113.9M; the latest was Later Stage VC ($35.0M) in Mar 2025.
- Notable investors include Plug and Play Tech Center, Y Combinator, Alumni Ventures, SOSV, Endeavor Catalyst — 37 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 37 names
- ·Watchlist + deal alerts for Mendel
- ·The full record, as it builds
Funding rounds
No funding rounds for Mendel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mendel
Developer of healthcare software designed to solve problems at each stage of the clinical trial process. The company's software combines machine precision and human intuition from feasibility to post-trial pharmacovigilance, as well as transforms unstructured data and clinical literature into comprehensive and analytics-ready data, enabling clinical experts to streamline global oncology research by automating clinical trials.
- Sector
- Healthcare
- HQ
- San Jose, CA, United States
- Founded
- 2016
- Employees
- 96
- Website
- mendel.ai/
- Ownership
- Privately Held (backing)
Mendel doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mendel shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mendel in its N-PORT filings yet. We sweep new filings monthly.